Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 869

Sort by

Sort Order Select

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Blood (2022) 140 (Supplement 1): 2130–2132.

https://doi.org/10.1182/blood-2022-169011

Published: 2022

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 195–197.

https://doi.org/10.1182/blood-2022-167177

Published: 2022

Journal Articles

Immunological Response to Sars-Cov-2 after Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients - a Prospective Study

Marisol Miranda, Ravindra Kolhe, Danielle Bradshaw, Jaspreet Farmaha, Kimya Jones, Harmanpreet Singh, Ashutosh Vashisht, Nikhil Sahajpal, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 12210.

https://doi.org/10.1182/blood-2022-170363

Published: 2022

Journal Articles

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Koji Sasaki, Michael Mauro, Moshe Yair Levy, Ehab L. Atallah, Paul B. Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 6784–6786.

https://doi.org/10.1182/blood-2022-167044

Published: 2022

Journal Articles

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Mahran Shoukier, Mycal Casey, Shreya Desai, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 13285–13286.

https://doi.org/10.1182/blood-2022-169316

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial

Vamsi K. Kota, Michael W. Deininger, Jason H. Mendler, Wei Shen, Erinn Hoag Goldman, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 6798–6799.

https://doi.org/10.1182/blood-2022-162428

Published: 2022

Journal Articles

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, KM Islam, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 5274–5275.

https://doi.org/10.1182/blood-2022-167092

Published: 2022

Journal Articles

Clinical Trial Success Rates of Investigational Antileukemic Drugs Presented at the American Society of Hematology (ASH) Meetings

Marisol Miranda, Thalyta Medeiros, Claudia Guillén Lopez, Kenza Mamouni, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 10843–10844.

https://doi.org/10.1182/blood-2022-170215

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Long-Term Results of the Treatment of Adolescents and Adults with Acute Lymphoblastic Leukemia with a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience

Elizabeth García-Villaseñor, Jorge E. Cortes, Oscar A. Reyes-Cisneros, José Antonio Fernández-Gutiérrez, Daniela Sánchez-Bonilla, Lorena Bojalil-Álvarez, Iván Murrieta-Álvarez, Guillermo José Ruiz-Delgado, Guillermo José Ruiz Argüelles

Blood (2022) 140 (Supplement 1): 11590–11591.

https://doi.org/10.1182/blood-2022-163602

Published: 2022

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Sandeep Anand Padala, Anusha Vakiti, Wendy Bollag, Jennifer Waller, Mufaddal Kheda, Stephanie L Baer, Ravindra Kolhe, Mohammad A.H. Mian, Anand P. Jillella, Jorge E. Cortes, Vamsi Kota

Blood (2022) 140 (Supplement 1): 7697–7698.

https://doi.org/10.1182/blood-2022-170672

Published: 2022

Journal Articles

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Blood (2022) 140 (Supplement 1): 546–548.

https://doi.org/10.1182/blood-2022-162739

Published: 2022

Journal Articles

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Mahran Shoukier, Monirul Islam, Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 13200–13201.

https://doi.org/10.1182/blood-2022-162403

Published: 2022

Journal Articles

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, Ronald Paquette, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 9624–9625.

https://doi.org/10.1182/blood-2022-163080

Published: 2022

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA

Aram Bidikian, Sreyashi Basu, He Zhong, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa

Blood (2022) 140 (Supplement 1): 6739–6741.

https://doi.org/10.1182/blood-2022-165509

Published: 2022

Journal Articles

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Elias Jabbour, Koji Sasaki, Ghayas C. Issa, Fadi Haddad, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Musa Yilmaz, Courtney D. DiNardo, Jeffrey Skinner, Naveen Pemmaraju, Sara E Dellasala, Sherry A. Pierce, Jorge E. Cortes, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 809–811.

https://doi.org/10.1182/blood-2022-169772

Published: 2022

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

NARROW

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Immunological Response to Sars-Cov-2 after Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients - a Prospective Study

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Clinical Trial Success Rates of Investigational Antileukemic Drugs Presented at the American Society of Hematology (ASH) Meetings

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Long-Term Results of the Treatment of Adolescents and Adults with Acute Lymphoblastic Leukemia with a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only